Global Carcinoid Tumor Insights 2025, Forecast To 2034
26 Mar, 2025
What Fueled The Previous Growth In The Carcinoid Tumor Market?
The carcinoid tumor market has seen considerable growth due to a variety of factors.
• The market size for carcinoid tumors has experienced quick expansion in the past few years. It is projected to surge from $1.61 billion in 2024 up to $1.78 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.7%.
The growth seen in the historical timeframe can be accredited to factors like increased occurrences of neuroendocrine tumors, heightened awareness regarding uncommon cancers, enhancements in healthcare infrastructure, the presence of targeted therapies, and the broadening scope of clinical trials for novel treatment alternatives.
What Is The Expected Growth In The Carcinoid Tumor Market in the Coming Years?
The carcinoid tumor market is expected to maintain its strong growth trajectory in upcoming years.
• A rise in the market size of carcinoid tumors is anticipated to greatly pick up over the coming years. The market is forecasted to expand to $2.65 billion by 2029, showcasing a compound annual growth rate (CAGR) of 10.5%.
Several factors add to this expected surge in the forecast period, such as the escalating demand for tailored medicine, an intensified emphasis on early identification and diagnosis, increased preference for minimally invasive procedures, broadening research into new treatments, and a heightened reliance on therapies targeting molecules. The forecast period will also bring with it significant trends like the incorporation of artificial intelligence and machine learning in diagnostics, a transition towards combination therapies, reliance on telemedicine and distant monitoring, a focus on patient-oriented care, as well as synergy in research.
Which Factors Are Boosting Growth In The Carcinoid Tumor Market?
The escalation in the carcinoid tumor market is projected to be driven by the increasing obesity rates. The term "obese population" refers to those individuals with a body mass index (BMI) exceeding 30, signifying an unhealthy amount of body fat. The rise in obesity rates can be connected to contributing factors such as unhealthy eating patterns, inactivity, sedentary lifestyles, and high consumption of processed and high-calorie foods. Obesity exacerbates the risks of developing a carcinoid tumor by fostering chronic inflammation, insulin resistance, and elevated secretion of growth factors, thereby encouraging tumor growth. The Centers for Disease Control and Prevention, a governmental agency based in the US, reported in September 2023 that 22 states recorded an adult obesity rate of 35% or more in 2022, marking an increase from 19 states the previous year. Consequently, the uptick in obesity rates is a driving force behind the growth of the carcinoid tumor market.
What Are The Primary Segments In The Global Carcinoid Tumor Market?
The carcinoid tumor market covered in this report is segmented –
1) By Disease Type: Gastrointestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Other Disease Types
2) By Treatment: Octreotide, Lanreotide, Telotristat ethyl, Capecitabine (Xeloda), 5-Fluorouracil (5-FU), Doxorubicin (Adriamycin), Etoposide (VP-1
6), Dacarbazine (DTIC), Streptozocin, Other Treatments
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Online Channel, Offline Channel
5) By End User: Hospital And Clinics, Academic Institutions, Research Organizations
Subsegments:
1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors
2) By Pancreatic Neuroendocrine Tumor: Insulinoma, Non-insulinoma, Glucagonoma
3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors, Atypical Carcinoid Tumors
4) By Other Disease Types: Thymic Neuroendocrine Tumors, Ovarian Neuroendocrine Tumors
Which Key Trends Are Driving Changes In The Carcinoid Tumor Market?
In the carcinoid tumor market, key players are prioritizing the progression of diagnostic technologies, such as the fully automated chromogranin A (CgA) test, to facilitate early detection and improve treatment results. The CgA test is a fully automated diagnostic instrument that measures chromogranin A levels, a biomarker often found in neuroendocrine tumors, including carcinoid tumors. For example, Thermo Fisher Scientific Inc., a biotechnology research firm based in the US, was granted FDA clearance for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay in October 2023. This approval marks the first FDA-sanctioned Chromogranin A (CgA) test and the only automated immunoassay available internationally for monitoring tumor growth in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. The assay is designed to measure CgA concentration in human serum, allowing labs and cancer centers to monitor tumor development and evaluate treatment effectiveness. By displacing manually conducted laboratory-developed tests, it aids in enhancing laboratory efficiency and providing more accurate result interpretation. The assessment is performed on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, employing TRACE technology to deliver accurate results in less than 30 minutes.
Who Are the Key Players In The Carcinoid Tumor Market?
Major companies operating in the carcinoid tumor market are:
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Sanofi S.A.
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Siemens Healthineers AG
• Boston Scientific Corporation
• Boehringer Ingelheim International GmbH
• Catalent Inc
• Ipsen S.A.
• Exelixis Inc
• Novocure Limited
• Hutchison MediPharma Limited (A subsidiary of HUTCHMED)
• Tarveda Therapeutics Inc.
• Lexicon Pharmaceuticals Inc.
• Dauntless Pharmaceuticals Inc.
What Is The Most Dominant Region In The Carcinoid Tumor Market?
North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.